Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + technetium Tc 99m rhenium sulfide
- Development stage
- Unknown
- Lead developer
- Jean Perrin Center at Clermont-Ferrand University Hospital
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
cisplatin + technetium Tc 99m rhenium sulfide is a combination of the platinum-based chemotherapeutic agent cisplatin and the radiopharmaceutical tracer Nanocis (technetium [99mTc] rhenium sulfide colloid). This combination is specifically utilized in the management of advanced ovarian cancer and peritoneal carcinomatosis via intraperitoneal (IP) administration. Following cytoreductive surgery, cisplatin is delivered directly into the peritoneal cavity to target residual microscopic disease. Nanocis is co-administered as a diagnostic radiotracer to perform IP scintigraphy, allowing clinicians to visualize the distribution of the chemotherapy within the abdominal cavity. This imaging helps identify potential distribution issues caused by postoperative adhesions and correlates drug accumulation with clinical outcomes or side effects like abdominal pain. Cisplatin exerts its cytotoxic effect by forming covalent cross-links with DNA, while Nanocis provides the gamma-emitting isotope for scintigraphic imaging.
- Brand names
- Nanocis
- Other names
- Intraperitoneal cisplatin with nanocis99mTc-Nanocis99mTc-rhenium sulfide colloid
02
Targets
DNA
Beyond the preview
Go deeper on cisplatin + technetium Tc 99m rhenium sulfide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + technetium Tc 99m rhenium sulfide.